Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcutis Biotherapeutics Inc (NQ: ARQT )

9.600 +0.720 (+8.11%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,830,086
Open 8.840
Bid (Size) 9.600 (10)
Ask (Size) 9.700 (13)
Prev. Close 8.880
Today's Range 8.560 - 9.630
52wk Range 1.760 - 13.17
Shares Outstanding 50,241,789
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Have $5-10? 7 Affordable Stocks That Are About to Breakout.
These stocks are already showing gains this year, but they are all still affordable stocks ready to breakout. 
Via InvestorPlace

Performance

YTD
+179.88%
+179.88%
1 Month
+8.11%
+8.11%
3 Month
+3.67%
+3.67%
6 Month
+209.68%
+209.68%
1 Year
+12.35%
+12.35%

More News

Read More
Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Evaluating Arcutis Biotherapeutics: Insights From 5 Financial Analysts
Via Benzinga
Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
NEXTracker Posts Upbeat Earnings, Joins monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
ARQT Stock Earnings: Arcutis Biotherapeutics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Arcutis Biotherapeutics Stock Climbs After Blockbuster Q1 Results
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Appoints David Topper as Chief Financial Officer
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
EQT, Genie Energy And Other Big Stocks Moving Lower On Monday
Via Benzinga
Topics Stocks
Exposures US Equities
Arcutis Promotes Todd Tucker to Chief Human Resources Officer
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Announces Pricing of $150 Million Public Offering
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Announces Proposed Public Offering
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.